http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021225466-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afb8acdeb99a4ab18faf321caaec610b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a86291c63f245efb1eecb233329fa1e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32e28f39f58263db5783815fa90b5f25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3201cb11df76183205b99fbe5199202 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c41f271d87fd7b8685fc23adf2fc4988 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383 |
| filingDate | 2021-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32c5f991e3da5c8d418ac817069b15f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d46d4e3193d776ecb2ee61b768bddea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d484fd28ed99567016868ef256a3ef17 |
| publicationDate | 2021-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021225466-A1 |
| titleOfInvention | Anti-coronavirus therapeutic agent - substituted 7-hydroxy-3,4,12,12a-tetrahydro-1h-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione for prophylaxis and treatment of covid-19 |
| abstract | The present invention relates to a new anti-coronavirus therapeutic agent – substituted 7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-ƒ][1,2,4]triazine-6,8-dione for the prophylaxis and treatment of SARS-CoV-2 (COVID-19). Claimed is an anti-coronavirus therapeutic agent comprising substituted 7-hydroxy-3,4,12,12a-tetrahydro-1H-1,4]oxazino[3,4-c]pyrido[2,1-ƒ][1,2,4]triazine-6,8-dione of general formula 1, its stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, its crystalline or polycrystalline form (I), where R1 is 6,7-difluoro-5,10-dihydrothieno[3,2-c] [2]benzothiepin-10-yl, 7,8-difluoro-4,9-dihydrothieno-[2,3-c[2]benzothiepin-4-yl, (3,4-difluorophenyl)(phenyl)methyl, (3,4-difluorophenyl(2-methylsulfanylphenyl(methyl, diphenyl methyl, bis(4-fluorophenyl)methyl; R2 is hydrogen or the group CH2OCO2(С1-С3alkyl). |
| priorityDate | 2020-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.